October 16, 2024
Holmes Chapel, UK; Wednesday 16th October 2024 - Today, specialist inhalation contract development and manufacturing organisation (CDMO) Bespak, announced that it is closing its site in North Carolina, US and transferring selected product development and testing activities to its Holmes Chapel, UK site.
The transfer of product development activity to Holmes Chapel represents a strategic milestone for Bespak, enabling greater focus on, and responsiveness to, customer needs in its core pressurised Metered Dose Inhaler (pMDI) business.
Bringing drug product development, manufacturing and testing together on one site will improve the integration of pMDI development-to-commercial activities, and follows recent announcements on the expansion of manufacturing capabilities and capacity to manufacture pMDIs using low global warming potential (GWP) propellants at both commercial- and pilot-scale at the Holmes Chapel site. This latest announcement, supported by Bespak’s market-leading position in metering valves, underpins its pMDI growth ambition.
Transfer activity will commence immediately in close collaboration with customers, with the goal that the site will fully close by the end of Q1 2025.
Chris Hirst, Bespak’s CEO, said: “This strategic decision reflects our vision to be the trusted innovation partner and sustainability leader for inhaled and nasal drug delivery, and is a natural progression of our evolution as a specialist inhalation CDMO. Operationally, this announcement enables us to fully focus on supporting our customers in their transition to climate-friendly low GWP propellants, creating the agility that is needed in today’s dynamic and competitive global pMDI market.”
For further information and interview opportunities with Bespak, please contact:
Sarah Guinane at Notch Communications
About Bespak:
Bespak is a specialist global contract development and manufacturing organisation (CDMO) solely focused on the inhaled and nasal drug delivery sector. It develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical industry. Headquartered in Holmes Chapel, UK, Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation, product development and clinical supply, through to full-scale cGMP batch production.
With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak also supplies a major proportion of the world’s pMDI metering valves and actuators. Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. The company has both established capacity and ongoing expansions to enable the manufacture of pMDIs with low Global Warming Potential (GWP) propellants HFA-152a & HFO-1234ze, making it ideally positioned to lead the green transition.
More information: www.bespak.com